2/2
10:09 pm
nktr
Nektar Therapeutics (NKTR): A Bull Case Theory [Yahoo! Finance]
Medium
Report
Nektar Therapeutics (NKTR): A Bull Case Theory [Yahoo! Finance]
1/30
05:58 pm
nktr
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
1/30
04:10 pm
nktr
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/29
12:30 pm
nktr
Nektar Therapeutics (NASDAQ:NKTR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $118.00 price target on the stock.
Low
Report
Nektar Therapeutics (NASDAQ:NKTR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $118.00 price target on the stock.
1/27
01:42 pm
nktr
An immune drug developer raises $50M to finance its eczema drug testing [Yahoo! Finance]
Low
Report
An immune drug developer raises $50M to finance its eczema drug testing [Yahoo! Finance]
1/26
10:59 am
nktr
Nektar Therapeutics (NASDAQ:NKTR) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Low
Report
Nektar Therapeutics (NASDAQ:NKTR) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
1/22
10:00 am
nktr
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
Medium
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
1/20
04:20 pm
nktr
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
1/15
10:00 am
nktr
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
1/13
04:28 pm
nktr
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
1/8
10:00 am
nktr
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
Medium
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
1/7
08:35 am
nktr
How The Narrative Around Nektar Therapeutics (NKTR) Is Shifting With Rezpeg Data And Litigation Risks [Yahoo! Finance]
Low
Report
How The Narrative Around Nektar Therapeutics (NKTR) Is Shifting With Rezpeg Data And Litigation Risks [Yahoo! Finance]
1/6
11:50 am
nktr
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
1/1
10:00 am
nktr
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
Medium
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
12/30
12:40 pm
nktr
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
12/21
07:42 am
nktr
Strong REZOLVE-AA Study Results Drive Analyst Confidence in Nektar Therapeutics (NKTR) [Yahoo! Finance]
Medium
Report
Strong REZOLVE-AA Study Results Drive Analyst Confidence in Nektar Therapeutics (NKTR) [Yahoo! Finance]
12/19
10:42 am
nktr
Nektar Therapeutics: Rezpeg's Phase 2b Alopecia Areata Results Leave Many Questions [Seeking Alpha]
Medium
Report
Nektar Therapeutics: Rezpeg's Phase 2b Alopecia Areata Results Leave Many Questions [Seeking Alpha]
12/19
10:36 am
nktr
Why Analysts Think Nektar Therapeutics Could Be Undervalued After Rezpeg Trial Momentum Grows [Yahoo! Finance]
Medium
Report
Why Analysts Think Nektar Therapeutics Could Be Undervalued After Rezpeg Trial Momentum Grows [Yahoo! Finance]
12/17
08:05 am
nktr
Nektar Therapeutics (NASDAQ:NKTR) had its price target raised by analysts at BTIG Research from $100.00 to $118.00. They now have a "buy" rating on the stock.
Medium
Report
Nektar Therapeutics (NASDAQ:NKTR) had its price target raised by analysts at BTIG Research from $100.00 to $118.00. They now have a "buy" rating on the stock.
12/17
07:06 am
nktr
Nektar Therapeutics (NASDAQ:NKTR) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
High
Report
Nektar Therapeutics (NASDAQ:NKTR) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
12/16
01:43 pm
nktr
iShares MSCI EAFE Growth ETF declares semi-annual distribution of $1.8057 [Seeking Alpha]
Medium
Report
iShares MSCI EAFE Growth ETF declares semi-annual distribution of $1.8057 [Seeking Alpha]
12/16
01:43 pm
nktr
iShares MSCI Indonesia ETF declares semi-annual distribution of $0.1615 [Seeking Alpha]
Medium
Report
iShares MSCI Indonesia ETF declares semi-annual distribution of $0.1615 [Seeking Alpha]
12/16
01:43 pm
nktr
iShares MSCI Emerging Markets Min Vol Factor ETF declares semi-annual distribution of $0.9748 [Seeking Alpha]
Medium
Report
iShares MSCI Emerging Markets Min Vol Factor ETF declares semi-annual distribution of $0.9748 [Seeking Alpha]
12/16
01:43 pm
nktr
iShares MSCI EAFE ETF declares semi-annual distribution of $1.7279 [Seeking Alpha]
Medium
Report
iShares MSCI EAFE ETF declares semi-annual distribution of $1.7279 [Seeking Alpha]
12/16
01:43 pm
nktr
iShares MSCI EAFE Min Vol Factor ETF declares semi-annual distribution of $1.1733 [Seeking Alpha]
Low
Report
iShares MSCI EAFE Min Vol Factor ETF declares semi-annual distribution of $1.1733 [Seeking Alpha]